Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.

Paajanen J, Laaksonen S, Kettunen E, Ilonen I, Vehmas T, Salo J, Räsänen J, Sutinen BHc E, Ollila BHc H, Mäyränpää MI, Myllärniemi M, Wolff H.

Hum Pathol. 2020 Mar 3. pii: S0046-8177(20)30048-4. doi: 10.1016/j.humpath.2020.02.007. [Epub ahead of print]

2.

Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, Rouvinen E, Lemström K, Räsänen J, Ritvos O, Koli K, Myllärniemi M.

Clin Lung Cancer. 2019 Oct 25. pii: S1525-7304(19)30287-6. doi: 10.1016/j.cllc.2019.10.013. [Epub ahead of print]

3.

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.

Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Kankaanranta H, Koli K, Vahlberg T, Myllärniemi M.

ERJ Open Res. 2019 Jul 8;5(3). pii: 00170-2018. doi: 10.1183/23120541.00170-2018. eCollection 2019 Jul.

4.

Inorganic particulate matter in the lung tissue of idiopathic pulmonary fibrosis patients reflects population density and fine particle levels.

Mäkelä K, Ollila H, Sutinen E, Vuorinen V, Peltola E, Kaarteenaho R, Myllärniemi M.

Ann Diagn Pathol. 2019 Jun;40:136-142. doi: 10.1016/j.anndiagpath.2019.04.011. Epub 2019 Apr 24.

5.

Malignant Peritoneal Mesothelioma: Treatment Options and Survival.

Salo SAS, Ilonen I, Laaksonen S, Myllärniemi M, Salo JA, Rantanen T.

Anticancer Res. 2019 Feb;39(2):839-845. doi: 10.21873/anticanres.13183.

PMID:
30711965
6.

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events.

Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, Melgaard Nielsen K, Münster AB, Myllärniemi M, Ravaglia C, Vanuytsel T, Wijsenbeek M.

Respiration. 2019;97(2):173-184. doi: 10.1159/000495046. Epub 2018 Dec 13. Review.

PMID:
30544129
7.

Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life.

Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllärniemi M, Saarto T.

BMC Pulm Med. 2018 Nov 20;18(1):172. doi: 10.1186/s12890-018-0738-x.

8.

Malignant pleural mesothelioma in Finland: regional and gender variation.

Laaksonen S, Ilonen I, Kuosma E, Sutinen E, Wolff H, Vehmas T, Husgafvel-Pursiainen K, Salo JA, Koli K, Räsänen J, Myllärniemi M.

Acta Oncol. 2019 Jan;58(1):38-44. doi: 10.1080/0284186X.2018.1532599. Epub 2018 Oct 30.

PMID:
30375909
9.

Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.

Li C, Rezov V, Joensuu E, Vartiainen V, Rönty M, Yin M, Myllärniemi M, Koli K.

Sci Rep. 2018 Jul 3;8(1):10070. doi: 10.1038/s41598-018-28297-x.

10.

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.

Pesonen I, Carlson L, Murgia N, Kaarteenaho R, Sköld CM, Myllärniemi M, Ferrara G.

Multidiscip Respir Med. 2018 May 14;13:14. doi: 10.1186/s40248-018-0126-7. eCollection 2018.

11.

Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice.

Vartiainen V, Raula J, Bimbo LM, Viinamäki J, Backman JT, Ugur N, Kauppinen E, Sutinen E, Joensuu E, Koli K, Myllärniemi M.

Int J Pharm. 2018 Jun 10;544(1):121-128. doi: 10.1016/j.ijpharm.2018.04.019. Epub 2018 Apr 12.

PMID:
29655797
12.

Analysis of the Histologic Features Associated With Interobserver Variation in Idiopathic Pulmonary Fibrosis.

Mäkelä K, Hodgson U, Piilonen A, Kelloniemi K, Bloigu R, Sutinen E, Salmenkivi K, Rönty M, Lappi-Blanco E, Myllärniemi M, Kaarteenaho R.

Am J Surg Pathol. 2018 May;42(5):672-678. doi: 10.1097/PAS.0000000000001031.

PMID:
29438171
13.

Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.

Paajanen J, Laaksonen S, Ilonen I, Wolff H, Husgafvel-Pursiainen K, Kuosma E, Ollila H, Myllärniemi M, Vehmas T.

Lung Cancer. 2018 Feb;116:73-79. doi: 10.1016/j.lungcan.2018.01.001. Epub 2018 Jan 4.

PMID:
29413055
14.

mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis.

Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllärniemi M, Saarto T.

ERJ Open Res. 2017 Dec 14;3(4). pii: 00084-2017. doi: 10.1183/23120541.00084-2017. eCollection 2017 Oct.

15.

Gremlin-1 is a key regulator of the invasive cell phenotype in mesothelioma.

Yin M, Tissari M, Tamminen J, Ylivinkka I, Rönty M, von Nandelstadh P, Lehti K, Hyytiäinen M, Myllärniemi M, Koli K.

Oncotarget. 2017 Oct 6;8(58):98280-98297. doi: 10.18632/oncotarget.21550. eCollection 2017 Nov 17.

16.

Epidemiology of malignant peritoneal mesothelioma: A population-based study.

Salo SAS, Ilonen I, Laaksonen S, Myllärniemi M, Salo JA, Rantanen T.

Cancer Epidemiol. 2017 Dec;51:81-86. doi: 10.1016/j.canep.2017.10.008. Epub 2017 Nov 5.

PMID:
29080447
17.

Are physicians in primary health care able to recognize pulmonary fibrosis?

Purokivi M, Hodgson U, Myllärniemi M, Salomaa ER, Kaarteenaho R.

Eur Clin Respir J. 2017 Feb 20;4(1):1290339. doi: 10.1080/20018525.2017.1290339. eCollection 2017.

18.

Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.

Sköld CM, Bendstrup E, Myllärniemi M, Gudmundsson G, Sjåheim T, Hilberg O, Altraja A, Kaarteenaho R, Ferrara G.

J Intern Med. 2017 Feb;281(2):149-166. doi: 10.1111/joim.12571. Epub 2016 Nov 13. Review.

19.

End-of-life care of patients with idiopathic pulmonary fibrosis.

Rajala K, Lehto JT, Saarinen M, Sutinen E, Saarto T, Myllärniemi M.

BMC Palliat Care. 2016 Oct 12;15(1):85.

20.

Gremlin-1 Overexpression in Mouse Lung Reduces Silica-Induced Lymphocyte Recruitment - A Link to Idiopathic Pulmonary Fibrosis through Negative Correlation with CXCL10 Chemokine.

Koli K, Sutinen E, Rönty M, Rantakari P, Fortino V, Pulkkinen V, Greco D, Sipilä P, Myllärniemi M.

PLoS One. 2016 Jul 18;11(7):e0159010. doi: 10.1371/journal.pone.0159010. eCollection 2016.

21.

Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries.

Bendstrup E, Hyldgaard C, Altraja A, Sjåheim T, Myllärniemi M, Gudmundsson G, Sköld M, Hilberg O.

Eur Clin Respir J. 2015 Jul 1;2. doi: 10.3402/ecrj.v2.28348. eCollection 2015.

22.

Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine.

Myllärniemi M, Kaarteenaho R.

Eur Clin Respir J. 2015 Feb 10;2. doi: 10.3402/ecrj.v2.26385. eCollection 2015. Review.

23.

Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis.

Kaunisto J, Kelloniemi K, Sutinen E, Hodgson U, Piilonen A, Kaarteenaho R, Mäkitaro R, Purokivi M, Lappi-Blanco E, Saarelainen S, Kankaanranta H, Mursu A, Kanervisto M, Salomaa ER, Myllärniemi M.

BMC Pulm Med. 2015 Aug 19;15:92. doi: 10.1186/s12890-015-0074-3.

24.

Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth.

Tamminen JA, Yin M, Rönty M, Sutinen E, Pasternack A, Ritvos O, Myllärniemi M, Koli K.

Exp Cell Res. 2015 Mar 1;332(1):102-15. doi: 10.1016/j.yexcr.2014.12.010. Epub 2014 Dec 31.

25.

Upregulation of alveolar levels of activin B, but not activin A, in lungs of west highland white terriers with idiopathic pulmonary fibrosis and diffuse alveolar damage.

Lilja-Maula L, Syrjä P, Laurila HP, Sutinen E, Palviainen M, Ritvos O, Koli K, Rajamäki MM, Myllärniemi M.

J Comp Pathol. 2015 Feb-Apr;152(2-3):192-200. doi: 10.1016/j.jcpa.2014.11.006. Epub 2014 Dec 30.

PMID:
25555634
26.

Upregulation of activin-B and follistatin in pulmonary fibrosis - a translational study using human biopsies and a specific inhibitor in mouse fibrosis models.

Myllärniemi M, Tikkanen J, Hulmi JJ, Pasternack A, Sutinen E, Rönty M, Leppäranta O, Ma H, Ritvos O, Koli K.

BMC Pulm Med. 2014 Nov 1;14:170. doi: 10.1186/1471-2466-14-170.

27.

Transforming growth factor beta 1 activation, storage, and signaling pathways in idiopathic pulmonary fibrosis in dogs.

Krafft E, Lybaert P, Roels E, Laurila HP, Rajamäki MM, Farnir F, Myllärniemi M, Day MJ, Mc Entee K, Clercx C.

J Vet Intern Med. 2014 Nov-Dec;28(6):1666-75. doi: 10.1111/jvim.12432. Epub 2014 Oct 20.

28.

[Respiratory depression caused by a fentanyl patch applied as a topical analgesic].

Myllärniemi M, Kauppi P.

Duodecim. 2014;130(17):1759-60. Finnish.

PMID:
25272787
29.

Idiopathic pulmonary fibrosis in the USA.

Myllärniemi M.

Lancet Respir Med. 2014 Jul;2(7):515-6. doi: 10.1016/S2213-2600(14)70117-1. Epub 2014 May 27. No abstract available.

PMID:
24875842
30.

Comparative study of transforming growth factor-β signalling and regulatory molecules in human and canine idiopathic pulmonary fibrosis.

Lilja-Maula L, Syrjä P, Laurila HP, Sutinen E, Rönty M, Koli K, Rajamäki MM, Myllärniemi M.

J Comp Pathol. 2014 May;150(4):399-407. doi: 10.1016/j.jcpa.2013.12.001. Epub 2013 Dec 10.

PMID:
24529509
31.

Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug.

Tamminen JA, Parviainen V, Rönty M, Wohl AP, Murray L, Joenväärä S, Varjosalo M, Leppäranta O, Ritvos O, Sengle G, Renkonen R, Myllärniemi M, Koli K.

Oncogenesis. 2013 Aug 26;2:e66. doi: 10.1038/oncsis.2013.29.

32.

Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data.

Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllärniemi M.

BMC Pulm Med. 2013 Aug 20;13:53. doi: 10.1186/1471-2466-13-53. Review.

33.

The histopathology of idiopathic pulmonary fibrosis in West Highland white terriers shares features of both non-specific interstitial pneumonia and usual interstitial pneumonia in man.

Syrjä P, Heikkilä HP, Lilja-Maula L, Krafft E, Clercx C, Day MJ, Rönty M, Myllärniemi M, Rajamäki MM.

J Comp Pathol. 2013 Aug-Oct;149(2-3):303-13. doi: 10.1016/j.jcpa.2013.03.006. Epub 2013 May 9.

PMID:
23664319
34.

Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo.

Leppäranta O, Tikkanen JM, Bespalov MM, Koli K, Myllärniemi M.

Am J Respir Cell Mol Biol. 2013 Apr;48(4):448-55. doi: 10.1165/rcmb.2012-0201OC.

PMID:
23258233
35.

Asbestos exposure induces alveolar epithelial cell plasticity through MAPK/Erk signaling.

Tamminen JA, Myllärniemi M, Hyytiäinen M, Keski-Oja J, Koli K.

J Cell Biochem. 2012 Jul;113(7):2234-47. doi: 10.1002/jcb.24094.

PMID:
22573546
36.

Regulation of TGF-β storage and activation in the human idiopathic pulmonary fibrosis lung.

Leppäranta O, Sens C, Salmenkivi K, Kinnula VL, Keski-Oja J, Myllärniemi M, Koli K.

Cell Tissue Res. 2012 Jun;348(3):491-503. doi: 10.1007/s00441-012-1385-9. Epub 2012 Mar 22.

PMID:
22434388
37.

[Idiopathic pulmonary fibrosis -- progress in sight].

Kaarteenaho R, Hodgson U, Myllärniemi M.

Duodecim. 2011;127(24):2639-45. Review. Finnish.

PMID:
22320106
38.

Cysteine-rich protein 1 is regulated by transforming growth factor-β1 and expressed in lung fibrosis.

Järvinen PM, Myllärniemi M, Liu H, Moore HM, Leppäranta O, Salmenkivi K, Koli K, Latonen L, Band AM, Laiho M.

J Cell Physiol. 2012 Jun;227(6):2605-12. doi: 10.1002/jcp.23000.

PMID:
21882188
39.

A novel screening method detects herpesviral DNA in the idiopathic pulmonary fibrosis lung.

Pulkkinen V, Salmenkivi K, Kinnula VL, Sutinen E, Halme M, Hodgson U, Lehto J, Jääskeläinen A, Piiparinen H, Kere J, Lautenschlager I, Lappalainen M, Myllärniemi M.

Ann Med. 2012 Mar;44(2):178-86. doi: 10.3109/07853890.2010.532151. Epub 2011 Jan 24.

PMID:
21254895
40.

Proteomic studies on receptor for advanced glycation end product variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.

Ohlmeier S, Mazur W, Salmenkivi K, Myllärniemi M, Bergmann U, Kinnula VL.

Proteomics Clin Appl. 2010 Jan;4(1):97-105. doi: 10.1002/prca.200900128. Epub 2010 Jan 7.

PMID:
21137019
41.

Latent TGF-β binding proteins (LTBPs) 1 and 3 differentially regulate transforming growth factor-β activity in malignant mesothelioma.

Vehviläinen P, Koli K, Myllärniemi M, Lindholm P, Soini Y, Salmenkivi K, Kinnula VL, Keski-Oja J.

Hum Pathol. 2011 Feb;42(2):269-78. doi: 10.1016/j.humpath.2010.07.005. Epub 2010 Nov 24.

PMID:
21106222
42.

Expression of Transcription Factor GATA-6 in Alveolar Epithelial Cells Is Linked to Neonatal Lung Disease.

Vähätalo R, Asikainen TM, Karikoski R, Kinnula VL, White CW, Andersson S, Heikinheimo M, Myllärniemi M.

Neonatology. 2011;99(3):231-40. doi: 10.1159/000317827. Epub 2010 Nov 12.

43.

Isolation, culture, and characterization of smooth muscle cells from human intracranial aneurysms.

Bygglin H, Laaksamo E, Myllärniemi M, Tulamo R, Hernesniemi J, Niemelä M, Laakso A.

Acta Neurochir (Wien). 2011 Feb;153(2):311-8. doi: 10.1007/s00701-010-0836-x. Epub 2010 Oct 10.

PMID:
20936486
44.

Hemoglobin α and β are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD.

Ishikawa N, Ohlmeier S, Salmenkivi K, Myllärniemi M, Rahman I, Mazur W, Kinnula VL.

Respir Res. 2010 Sep 13;11:123. doi: 10.1186/1465-9921-11-123.

45.

Cell-specific elevation of NRF2 and sulfiredoxin-1 as markers of oxidative stress in the lungs of idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.

Mazur W, Lindholm P, Vuorinen K, Myllärniemi M, Salmenkivi K, Kinnula VL.

APMIS. 2010 Sep 1;118(9):703-12. doi: 10.1111/j.1600-0463.2010.02646.x.

PMID:
20718723
46.

ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses.

Pulkkinen V, Bruce S, Rintahaka J, Hodgson U, Laitinen T, Alenius H, Kinnula VL, Myllärniemi M, Matikainen S, Kere J.

FASEB J. 2010 Apr;24(4):1167-77. doi: 10.1096/fj.09-138545. Epub 2009 Dec 4.

PMID:
19966137
47.

Reduced phosphorylation of the TGF-Beta signal transducer Smad2 in emphysematous human lung.

Leppäranta O, Myllärniemi M, Salmenkivi K, Kinnula VL, Keski-Oja J, Koli K.

COPD. 2009 Aug;6(4):234-41.

PMID:
19811381
48.

Matrix metalloproteinases-7, -8, -9 and TIMP-1 in the follow-up of diisocyanate-induced asthma.

Piirilä P, Lauhio A, Majuri ML, Meuronen A, Myllärniemi M, Tervahartiala T, Vuorinen K, Laitinen A, Alenius H, Kinnula VL, Sorsa T.

Allergy. 2010 Jan;65(1):61-8. doi: 10.1111/j.1398-9995.2009.02146.x.

PMID:
19804449
49.

Transcription factor GATA-6 is expressed in quiescent myofibroblasts in idiopathic pulmonary fibrosis.

Leppäranta O, Pulkkinen V, Koli K, Vähätalo R, Salmenkivi K, Kinnula VL, Heikinheimo M, Myllärniemi M.

Am J Respir Cell Mol Biol. 2010 May;42(5):626-32. doi: 10.1165/rcmb.2009-0021OC. Epub 2009 Jul 13.

PMID:
19597127
50.

Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease.

Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, Myllärniemi M, Kinnula VL.

J Proteome Res. 2008 Dec;7(12):5125-32. doi: 10.1021/pr800423x.

PMID:
19367700

Supplemental Content

Loading ...
Support Center